IN2013MN01547A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01547A
IN2013MN01547A IN1547MUN2013A IN2013MN01547A IN 2013MN01547 A IN2013MN01547 A IN 2013MN01547A IN 1547MUN2013 A IN1547MUN2013 A IN 1547MUN2013A IN 2013MN01547 A IN2013MN01547 A IN 2013MN01547A
Authority
IN
India
Prior art keywords
wounds
treating
molecular target
ptprk
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Wenguo Jiang
Keith Harding
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of IN2013MN01547A publication Critical patent/IN2013MN01547A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/29Antimony or bismuth compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121Hammerhead
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN1547MUN2013 2011-03-08 2012-02-17 IN2013MN01547A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1103898.1A GB201103898D0 (en) 2011-03-08 2011-03-08 Molecular targets for healing or treating wounds
PCT/GB2012/050362 WO2012120269A1 (en) 2011-03-08 2012-02-17 Molecular targets for healing or treating wounds

Publications (1)

Publication Number Publication Date
IN2013MN01547A true IN2013MN01547A (ja) 2015-06-12

Family

ID=43923365

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1547MUN2013 IN2013MN01547A (ja) 2011-03-08 2012-02-17

Country Status (10)

Country Link
US (2) US20140213629A1 (ja)
EP (1) EP2683823B1 (ja)
JP (1) JP5986116B2 (ja)
CN (1) CN103443276B (ja)
AU (1) AU2012226593B2 (ja)
CA (1) CA2829010A1 (ja)
GB (2) GB201103898D0 (ja)
HK (1) HK1192904A1 (ja)
IN (1) IN2013MN01547A (ja)
WO (1) WO2012120269A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183062A1 (en) 2013-05-10 2014-11-13 La Jolla Institute For Allergy And Immunology Autoimmune disease treatments
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
US20220143210A1 (en) * 2019-02-27 2022-05-12 Fred Hutchinson Cancer Research Center Hydrogel compositions and methods for treatement of malignancies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204000B1 (en) 1995-04-28 2001-03-20 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
US20050215629A1 (en) 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
AU2002339904A1 (en) * 2001-09-07 2003-09-09 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US7844214B2 (en) 2002-03-02 2010-11-30 Nokia Corporation System and method for broadband digital broadcasting
EP1482966B1 (en) * 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
US20040009597A1 (en) * 2002-07-03 2004-01-15 Isis Pharmaceuticals Inc. Antisense modulation of PTPRK expression
CA2506619A1 (en) 2002-11-18 2004-08-19 Thomas W. Hodge Cell lines and host nucleic acid sequences related to infectious disease
JP2006517092A (ja) 2002-11-27 2006-07-20 アルテシアン セラピューティック,インコーポレイティド 心不全遺伝子の決定及び治療薬スクリーニング
GB2396106B (en) * 2002-12-12 2006-11-15 Johnson & Johnson Medical Ltd Wound dressings comprising enzyme inhibitors
AU2004274973A1 (en) 2003-09-19 2005-03-31 Aviaradx, Inc. Predicting breast cancer treatment outcome
US20050170445A1 (en) 2004-01-07 2005-08-04 Duke University Methods of establishing profiles for use in evaluating wound healing and biocompatibility of implant materials and microarrays useful therefor
WO2006108225A1 (en) 2005-04-11 2006-10-19 Garvan Institute Of Medical Research Method of screening for compounds that modulate cell proliferation
US20090203006A1 (en) 2006-05-01 2009-08-13 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Biological markers of chronic wound tissue and methods of using for criteria in surgical debridement
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2242852A4 (en) 2007-12-07 2011-02-09 Univ Oregon Health & Science PROCEDURE FOR DETERMINING WHETHER AN INDIVIDUAL REQUIRES A BCR ABL INHIBITOR
US20110305703A1 (en) 2008-12-08 2011-12-15 Vegenics Pty Limited Isolated vegf-c and vegf-d peptides and uses thereof
US20120190042A1 (en) 2009-01-22 2012-07-26 Reuben Gobezie Protein biomarkers and therapeutic targets for osteoarthritis
CN101671729B (zh) 2009-09-07 2012-09-05 张力建 用于肺癌治疗方案选择和/或预后评估的基因群、基因芯片和检测试剂盒
GB0916124D0 (en) 2009-09-15 2009-10-28 Univ Cardiff Method and kit for the classification and prognosis of wounds

Also Published As

Publication number Publication date
EP2683823B1 (en) 2016-07-20
HK1192904A1 (zh) 2014-09-05
US20140213629A1 (en) 2014-07-31
WO2012120269A1 (en) 2012-09-13
CN103443276A (zh) 2013-12-11
JP2014511392A (ja) 2014-05-15
GB201103898D0 (en) 2011-04-20
GB2502017A (en) 2013-11-13
CA2829010A1 (en) 2012-09-13
GB201314859D0 (en) 2013-10-02
US20160331716A1 (en) 2016-11-17
CN103443276B (zh) 2016-09-28
AU2012226593A1 (en) 2013-09-12
US9782381B2 (en) 2017-10-10
EP2683823A1 (en) 2014-01-15
AU2012226593B2 (en) 2016-06-02
JP5986116B2 (ja) 2016-09-06

Similar Documents

Publication Publication Date Title
CY1117655T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
AU2011328009A8 (en) Compounds and methods for treating pain
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
BR112013006673A2 (pt) produtos terapêuticos para câncer de mama
EP3195868A3 (en) Therapeutic use of a tlr agonist and combination therapy
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
MX2010003095A (es) Antidotos para inhibidores del factor xa y metodos para usar los mismos.
MX2012013731A (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
BR112013020159A2 (pt) método para inibir células tumorais de hamartoma
MX2019007057A (es) Composiciones de adenovirus.
EP3818991A3 (en) Compositions and methods for treating diseases
WO2016090024A3 (en) Combination therapy for treatment of cancer
MX342313B (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
MX2015007719A (es) Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MY173174A (en) Short bio-active peptides for promoting wound healing
IN2013MN01547A (ja)
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2013002539A (es) Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas.
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.